Pfizer Clinical Trial Pipeline — 227 Active Studies

Pfizer pipeline at a glance (March 2026)

About the Pfizer clinical program

Pfizer's clinical pipeline spans oncology, rare disease, infectious disease, and inflammation. In oncology, Ibrance (palbociclib) remains a mainstay of HR+ breast cancer treatment with ongoing combination trials, while Lorbrena (lorlatinib) anchors the ALK-positive NSCLC franchise. The 2023 acquisition of Seagen brought Padcev (enfortumab vedotin) and Tukysa (tucatinib) — expanding Pfizer's ADC and HER2 capabilities significantly. In rare disease, Pfizer's hemophilia gene therapy program and pipeline in Pompe disease and Duchenne MD represent major development investments. Their mRNA platform, validated by the COVID vaccine, is being applied to influenza, RSV, and oncology vaccine targets.

Key therapeutic areas

• Oncology (breast, NSCLC, urothelial, hematology)
• Rare disease / gene therapy
• Inflammation / immunology
• Infectious disease / vaccines
• mRNA therapeutics

Key pipeline programs

• Ibrance (palbociclib) — CDK4/6 inhibitor, HR+ breast cancer
• Lorbrena (lorlatinib) — ALK-positive NSCLC
• Padcev (enfortumab vedotin) — urothelial ADC
• Tukysa (tucatinib) — HER2+ breast/gastric/CRC
• Xtandi (enzalutamide) — prostate cancer
• Braftovi (encorafenib) — BRAF-mutant tumors

Top Pfizer trial indications

Condition / Indication	Trials
["Healthy"]	9
["Migraine"]	8
["Multiple Myeloma"]	8
["Breast Cancer"]	7
["Ulcerative Colitis"]	6
["Sickle Cell Disease"]	4
["Alopecia Areata"]	4
["Pneumococcal Disease"]	4

Why monitor Pfizer's clinical trial activity

Pfizer's Seagen acquisition pipeline is actively generating new combination trials across Padcev, Tukysa, and tisotumab vedotin. Their Phase 3 program in urothelial cancer, HER2+ tumors, and cervical cancer is one of the fastest-growing competitive spaces in oncology.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Pfizer's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Pfizer trials

• Sponsor normalization: Pfizer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What oncology programs is Pfizer actively trialing?

Pfizer's most active oncology trial areas include breast cancer (Ibrance CDK4/6 combinations, Tukysa HER2 combinations), urothelial cancer (Padcev combinations), NSCLC (Lorbrena, BRAF-targeted therapies), and prostate cancer (Xtandi combinations). The Seagen pipeline also contributes tisotumab vedotin for cervical cancer.

How many Pfizer trials are currently recruiting?

Based on current ClinicalTrials.gov data, 83 Pfizer-sponsored trials are actively recruiting patients globally.

Can DataLookout alert me when Pfizer initiates a new trial in my indication?

Yes. Create a watchlist combining Pfizer as a sponsor filter with your indication or mechanism keywords. You'll receive a daily digest whenever new Pfizer-sponsored trials matching those criteria are registered or updated.